Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia

Seymour, John F.; Döhner, Hartmut; Minden, Mark D.; Stone, Richard; Gambini, Dominique; Dougherty, Donna; Beach, C. L.; Weaver, Jerry; Dombret, Herve

Erstveröffentlichung

2017

Metadata only
Search for full text

Wissenschaftlicher Artikel

Autoren

Seymour, John F.

Döhner, Hartmut

Minden, Mark D.

Stone, Richard

Gambini, Dominique

et al.

Institutionen

UKU. Klinik für Innere Medizin III

Erschienen in

Leukemia & Lymphoma ; 58 (2017), 6. - S. 1412-1423. - ISSN 1042-8194. - eISSN 1029-2403

Link zur Veröffentlichung

https://dx.doi.org/10.1080/10428194.2016.1243680

Förderinformationen

Celgene Corporation

Schlagwörter

Azacitidine; hospitalization; treatment-emergent adverse event; AE; TEAE; risk myelodysplastic syndromes; dna methyltransferase inhibitors; quality-of-life; management; adults; 5-azacytidine; mortality; diagnosis; cells; time

DDC-Sachgruppe

DDC 610 / Medicine & health

Metadata

Zur Langanzeige